Anti-inflammatory psychopharmacology: Trials using low-dose anti-inflammatory agents (e.g., NSAIDs, minocycline, NLRP3 inhibitors) in depression offer a precedent for targeting inflammation in stress-linked psychiatric disorders. This evidence concerns the gene NLRP3 and psychiatric disorder.